Prestige Biologics Co., Ltd. (KOSDAQ:334970)
South Korea
· Delayed Price · Currency is KRW 3,235.00
+15.00 (0.47%)
At close: Dec 5, 2025
Prestige Biologics Income Statement
Financials in millions KRW. Fiscal year is July - June.
Millions KRW. Fiscal year is Jul - Jun.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Operating Revenue | 13,359 | 12,533 | 2,169 | 1,746 | 15.57 | 3,227 | Upgrade
|
| Other Revenue | - | - | - | -0 | -0 | - | Upgrade
|
| Revenue | 13,359 | 12,533 | 2,169 | 1,746 | 15.57 | 3,227 | Upgrade
|
| Revenue Growth (YoY) | 736.63% | 477.82% | 24.24% | 11115.88% | -99.52% | - | Upgrade
|
| Cost of Revenue | 25,887 | 28,517 | 11,013 | 1,252 | 24.28 | 880.08 | Upgrade
|
| Gross Profit | -12,528 | -15,984 | -8,844 | 493.75 | -8.71 | 2,347 | Upgrade
|
| Selling, General & Admin | 8,517 | 8,992 | 9,695 | 7,639 | 5,202 | 3,770 | Upgrade
|
| Research & Development | 11,111 | 2,588 | 9,301 | 31,848 | 30,970 | 25,097 | Upgrade
|
| Amortization of Goodwill & Intangibles | 49.4 | 49.06 | 51.91 | 47.89 | 49.36 | 50.98 | Upgrade
|
| Other Operating Expenses | 301.56 | 340.46 | 417.59 | 237.71 | 180.45 | 82.61 | Upgrade
|
| Operating Expenses | 25,440 | 17,698 | 24,586 | 40,536 | 36,623 | 29,184 | Upgrade
|
| Operating Income | -37,968 | -33,682 | -33,430 | -40,043 | -36,631 | -26,837 | Upgrade
|
| Interest Expense | -8,264 | -8,734 | -11,769 | -5,273 | -3,929 | -763.51 | Upgrade
|
| Interest & Investment Income | 316.94 | 519.37 | 1,468 | 853.79 | 700.85 | 265.21 | Upgrade
|
| Currency Exchange Gain (Loss) | -258.18 | 3,243 | -4,690 | -4,624 | -9,537 | 296.68 | Upgrade
|
| Other Non Operating Income (Expenses) | 12,302 | 11,191 | 18,957 | 10,222 | 257.62 | -12,339 | Upgrade
|
| EBT Excluding Unusual Items | -33,872 | -27,463 | -29,465 | -38,863 | -49,138 | -39,378 | Upgrade
|
| Gain (Loss) on Sale of Assets | -8.6 | -6.86 | 90.87 | 67.29 | 66.42 | - | Upgrade
|
| Asset Writedown | - | - | - | -646.03 | -646.03 | - | Upgrade
|
| Pretax Income | -33,881 | -27,469 | -29,374 | -39,442 | -49,718 | -39,378 | Upgrade
|
| Net Income | -33,881 | -27,469 | -29,374 | -39,442 | -49,718 | -39,378 | Upgrade
|
| Net Income to Common | -33,881 | -27,469 | -29,374 | -39,442 | -49,718 | -39,378 | Upgrade
|
| Shares Outstanding (Basic) | 78 | 74 | 61 | 59 | 52 | 44 | Upgrade
|
| Shares Outstanding (Diluted) | 78 | 74 | 61 | 59 | 52 | 44 | Upgrade
|
| Shares Change (YoY) | 27.53% | 20.50% | 4.32% | 13.35% | 16.44% | 25.46% | Upgrade
|
| EPS (Basic) | -434.46 | -372.51 | -480.00 | -672.37 | -960.73 | -886.00 | Upgrade
|
| EPS (Diluted) | -434.46 | -372.51 | -480.00 | -672.37 | -960.73 | -886.00 | Upgrade
|
| Free Cash Flow | -11,290 | -23,534 | -16,867 | -60,265 | -118,767 | -123,142 | Upgrade
|
| Free Cash Flow Per Share | -144.78 | -319.14 | -275.63 | -1027.35 | -2295.00 | -2770.68 | Upgrade
|
| Gross Margin | -93.78% | -127.53% | - | 28.28% | -55.97% | 72.73% | Upgrade
|
| Operating Margin | -284.20% | -268.74% | -1541.23% | -2293.61% | -235333.31% | -831.68% | Upgrade
|
| Profit Margin | -253.61% | -219.17% | -1354.23% | -2259.19% | -319407.01% | -1220.33% | Upgrade
|
| Free Cash Flow Margin | -84.51% | -187.77% | -777.63% | -3451.94% | -763002.69% | -3816.18% | Upgrade
|
| EBITDA | -24,287 | -20,598 | -22,199 | -31,629 | -28,693 | -22,916 | Upgrade
|
| EBITDA Margin | -181.80% | -164.35% | - | - | - | - | Upgrade
|
| D&A For EBITDA | 13,681 | 13,083 | 11,231 | 8,414 | 7,938 | 3,921 | Upgrade
|
| EBIT | -37,968 | -33,682 | -33,430 | -40,043 | -36,631 | -26,837 | Upgrade
|
| EBIT Margin | -284.20% | -268.74% | - | - | - | - | Upgrade
|
| Advertising Expenses | - | 101.46 | 308.97 | - | 53.15 | 39.82 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.